Plus Therapeutics to Host Investor Call to Discuss Leptomeningeal Cancer Related Acquisition and Topline Clinical Trial Data from the FORESEE Trial
May 08, 2024 17:35 ET
|
Plus Therapeutics Inc.
Plus Therapeutics to Host Investor Call to Discuss Leptomeningeal Cancer Related Acquisition and Topline Clinical Trial Data from the FORESEE Trial
Dianthus Therapeutics to Participate in the Bank of America Securities 2024 Health Care Conference
May 08, 2024 16:30 ET
|
Dianthus Therapeutics, Inc.
NEW YORK and WALTHAM, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of...
Ballad Health, Niswonger Foundation Make Lifesaving Investment to Enhance Availability of Kidneys for Transplant, Reduce Costs of Care
May 08, 2024 16:16 ET
|
Ballad Health
JOHNSON CITY, Tenn., May 08, 2024 (GLOBE NEWSWIRE) -- More than 100,000 people are currently on the national transplant waiting list for a kidney. While waiting, most must rely upon expensive and...
Oculis Reports Q1 2024 Financial Results and Provides Company Updates
May 08, 2024 16:10 ET
|
Oculis Holding AG
Clinical programs progressing as planned with initiation of second OCS-01 Phase 3 DIAMOND-2 trial in Diabetic Macular Edema (DME) and completion of enrollment in OCS-02 (licaminlimab) Phase 2b RELIEF...
CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)
May 08, 2024 16:10 ET
|
CytomX Therapeutics Inc.
- CX-904 demonstrated a favorable safety profile with no cytokine release syndrome (CRS) of any grade observed in step-dosing cohorts and no grade >1 CRS observed overall - - Encouraging initial...
CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 08, 2024 16:10 ET
|
CytomX Therapeutics Inc.
- Company announces positive initial Phase 1a dose escalation data for monotherapy CX-904 (EGFRxCD3 T-cell engager) in solid tumors - - First dose cohort cleared in Phase 1 clinical study of CX-2051,...
89bio to Participate in the BofA Securities 2024 Health Care Conference
May 08, 2024 16:05 ET
|
89bio, Inc.
SAN FRANCISCO, May 08, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
Oculis Announces Completion of Enrollment in Phase 2 Randomized Controlled ACUITY Trial with OCS-05 for Acute Optic Neuritis
May 08, 2024 16:05 ET
|
Oculis Holding AG
Topline results anticipated in Q4 2024 for Phase 2 trial evaluating the safety and tolerability of OCS-05 in patients with Acute Optic Neuritis (AON)Oculis also aims to complete an IND submission for...
ZimVie Reports First Quarter 2024 Financial Results
May 08, 2024 16:05 ET
|
ZimVie Inc.
Third Party Net Sales from Continuing Operations of $118.2 millionNet Loss from Continuing Operations of ($11.5) million; Net Loss margin of (9.7%) Adjusted EBITDA[1] from Continuing Operations of...
Target Continuum Kicks off 2024 with Groundbreaking Partnership with Rehavior
May 08, 2024 14:11 ET
|
Target Continuum
Indianapolis, Indiana, May 08, 2024 (GLOBE NEWSWIRE) -- Target Continuum, a leader in healthcare marketing, proudly announces a pioneering partnership with Rehavior, an innovative technology...